Categories: CancerDiagnosticsNews

EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT

LYON, France, May 2, 2024 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date: Thursday, May 16th  
Time: 8:30 am EDT
Domestic: 1-877-451-6152
International: 1-201-389-0879
Passcode: 13745791
CallMeTM LINK (active 15 minutes prior to conference call)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1665376&tp_key=00daa24457

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.comus.hifu-prostate.com and www.focalone.com.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com

 

Staff

Recent Posts

Santiam Hospital and Clinics enters into Prime Vendor agreement with Medline

Oregon-based hospital taps into Medline's custom pack capabilities and distribution services NORTHFIELD Ill., June 9,…

9 hours ago

20/20NOW Advances Tele-Optometry with New VP of Professional Services Dr. Noelle Tchang OD and Spotlights Telehealth at Digital EyeCon

HOLBROOK, N.Y., June 9, 2025 /PRNewswire/ -- 20/20NOW, a pioneer in ocular telehealth, proudly announces…

9 hours ago

Business Integra Launches Mission-Ready Healthcare Staffing Solutions Backed by AI Technology

BETHESDA, Md., June 9, 2025 /PRNewswire/ -- Business Integra (BI), a leader in mission-critical talent solutions,…

9 hours ago

Imre Introduces the AI Conversation Converter

Agency launches First-in-Kind platform to quickly insert healthcare brands directly into the AI conversation NEW…

9 hours ago

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

New collaboration delivers 50% off prescription sleep support for new customers who are struggling with…

15 hours ago